Hyland M E, Kenyon C A, Jacobs P A
Department of Psychology, University of Plymouth, UK.
Qual Life Res. 1994 Apr;3(2):121-6. doi: 10.1007/BF00435255.
The quality of life (QOL) benefits of salmeterol versus placebo were compared in a double-blind, multicentre study using the Living with Asthma Questionnaire (LWAQ) which was scored in three different ways. First, the overall LWAQ score showed that salmeterol enhanced QOL compared to placebo. Second, when the LWAQ was analysed in terms of its two construct subscales we found, as predicted previously, that the Problem construct was more sensitive to longitudinal change compared with the Evaluation construct. Third, when the LWAQ was analysed in terms of its 11 domain subscales we found a significant improvement for salmeterol compared with placebo on three domains, Sport, Sleep, and Work and other activities. Analysing clinical trial results in terms of construct subscales and domain subscales provides different kinds of information each of which is useful. Analysis in terms of overall QOL scores is less informative.
在一项双盲、多中心研究中，使用哮喘生活问卷（LWAQ）（该问卷有三种不同的评分方式）比较了沙美特罗与安慰剂对生活质量（QOL）的益处。首先，LWAQ的总体评分显示，与安慰剂相比，沙美特罗提高了生活质量。其次，当根据LWAQ的两个结构子量表进行分析时，我们如先前预测的那样发现，与评估结构相比，问题结构对纵向变化更敏感。第三，当根据LWAQ的11个领域子量表进行分析时，我们发现与安慰剂相比，沙美特罗在运动、睡眠、工作和其他活动这三个领域有显著改善。根据结构子量表和领域子量表分析临床试验结果可提供不同类型的信息，每种信息都很有用。根据总体生活质量评分进行分析提供的信息较少。
